An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with Teriflunomide 7mg Once Daily and 14 mg Once Daily versus Placebo in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis, Sanofi-Aventis.